Syed Ibrahim Bukhari: Transforming the Diagnosis of IBMFC through Genomic in LMICs
Syed Ibrahim Bukhari, Clinical Fellow at The Hospital for Sick Children, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Expert Review of Hematology, adding:
“Proud to share our recent publication in Expert Review of Hematology
Genetic insights and diagnostic challenges in inherited bone marrow failure syndromes: a comprehensive study from a low middle-income country
Inherited bone marrow failure syndromes (IBMFS) are rare, complex, and frequently misdiagnosed as idiopathic aplastic anemia—especially in resource-limited settings where access to advanced diagnostics remains challenging.
In our pediatric cohort, genomic testing proved transformative:
- 34% diagnostic yield with confirmed molecular diagnoses
- Several children had their original diagnosis revised after genetic testing
- Commonly affected genes included MPL, FANCA, and DNAJC21
- Findings directly impacted treatment decisions, donor selection for HSCT, and family counseling
- High rates of VUS highlighted the urgent need for better South Asian representation in global genomic databases
Why this matters:
For children with marrow failure, the correct diagnosis can mean the difference between immunosuppressive therapy, disease-specific treatment, or urgent transplant planning.
Our study reinforces that precision medicine should not be limited by geography.
Grateful to my co-authors, mentors, and all families who made this work possible.”
Title: Genetic insights and diagnostic challenges in inherited bone marrow failure syndromes: a comprehensive study from a low middle-income country
Authors: Syed Ibrahim Bukhari, Fizza Akbar, Salman Kirmani, Zehra Fadoo, Asim Fakhruddin Belgaumi, Sadaf Altaf

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support